Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.
You may also be interested in...
A Long Way Still For Corrupt Business Practices In China, India - Pharmaceutical Regulatory And Compliance Congress
SINGAPORE - Major Chinese pharma companies are eyeing acquisitions of companies in lucrative Western markets to establish a global foothold, according to industry observers
While companies are feeling pressure to voluntarily disclose potential violations of the U.S. Foreign Corrupt Practices Act, it may not always be the most prudent action, former government attorneys suggested at a recent meeting
Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act